Composition and its use

A composition and drug technology, applied in the field of preparation of drugs for preventing and treating tissue fibrosis, can solve problems such as unclear mechanism of action, and achieve good effects and great development prospects.

Inactive Publication Date: 2007-01-24
杭州赐富生物技术有限公司 +1
View PDF0 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

On the other hand, the fermented culture of Cordyceps sinensis has been found to inhibit liver fibrosis and

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition and its use
  • Composition and its use
  • Composition and its use

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0066] Embodiment 1: preparation of fermented cryptoporus powder

[0067] Proceed as follows:

[0068] (1) Strain activation: the cryptoporous strains preserved at 4°C were transplanted into the following medium through aseptic operation, and cultured at the conventional fungal culture temperature for 8 days.

[0069] Culture medium component and weight percentage are (%):

[0070] Glucose 0.6

[0071] Maltose 1.5

[0072] Peptone 0.1

[0073] Yeast powder 0.8

[0074] K H 2 PO 4 0.1

[0075] MgSO 4 ·7H 2 O 0.05

[0076] Vitamin B 1 0.07

[0077] Agar 2.7

[0078] pH 4.8

[0079] The rest is water

[0080] (2) Shake flask culture: transfer the above-mentioned activated Cryptoporia hyphae into a 500mL Erlenmeyer flask containing 200mL of the following culture solution, and shake it in a shaking table at a shaking frequency of 200rpm and a temperature of 20-30°C for 6 sky;

[0081] Culture fluid composition and quality (%) are:

[0082] Glucos...

Embodiment 2

[0104] Embodiment 2: preparation of fermented Cordyceps sinensis powder

[0105] The asexual generation strain of Cordyceps sinensis in China is fermented on the liquid medium to obtain the fermentation supernatant, mycelia and various metabolites in it: the fermentation method is successively slant culture, shake flask seed culture, and one Grade and grade two seed tank culture, aeration culture in liquid fermenter, 50, 10, 6, 6, 10 days respectively at 10-18°C and pH 6.0-7.5.

[0106] The liquid culture medium (percentage by weight) is: silkworm chrysalis powder 2.0%, peptone 1.5%, corn flour 1.8%, sucrose 1.6%, dipotassium hydrogen phosphate 0.1%, magnesium sulfate 0.05%, the rest is water, feeds sterile Air.

[0107] After the fermentation is completed, solid-liquid separation is carried out to obtain mycelium and fermentation liquid, and the fermentation liquid is then subjected to membrane separation to obtain a fermentation filtrate rich in active ingredients. After th...

Embodiment 3

[0109] formula:

[0110] Embodiment 2 gained fermentation Cordyceps sinensis powder 5000g

[0111] 5000g of the obtained fermented cryptoporus powder of embodiment 1;

[0112] The above-mentioned fermented Cordyceps sinensis powder and fermented cryptoporus powder are evenly mixed to obtain the composition.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention provides a kind of composition comprising aweto or its fermented culture 20-80 wt% and cryptoporu volvatus or its fermented culture 20-80 wt%. The composition can inhibit fibrosis of lung and fibrosis of cardiac and cerebral vascular tissue, and possesses tissue fibrosis inhibiting effect obviously higher than that of available medicine interferon gamma. The composition has synergistic tissue fibrosis inhibiting effects of both aweto and cryptoporu volvatus and has no any toxic side effect found.

Description

(1) Technical field [0001] The invention relates to a composition and its application in the preparation of medicines for preventing and treating tissue fibrosis. (2) Background technology [0002] Tissue fibrosis is the common consequence of many different tissue injuries, and it is also the basic pathological change of many diseases that seriously threaten human health. In fact, tissue fibrosis affects almost all organs and systems of the human body, and is the main cause of disability and death in many diseases. According to relevant statistical data, nearly 45% of the patients who died of various diseases in the United States can be attributed to tissue fibrosis. Indeed, tissue fibrosis plays an important role in the occurrence and development of diseases in major organs of the human body. For example, cardiovascular tissue fibrosis plays an important role in the remodeling of cardiovascular tissue caused by hypertension and heart failure, and is also one of the main c...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K36/068A61P43/00
Inventor 胡卓伟柯传奎崔冰杨红振刘玉英陈黎郭新军
Owner 杭州赐富生物技术有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap